Actively Recruiting
Variations in the Hemostatic System Induced by a Standardized Walking Test
Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2025-02-19
94
Participants Needed
1
Research Sites
111 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Two groups of patients will be compared: One group of patients with a history of venous thromboembolic disease and one group without. Both groups will be subjected to a walking test and with electrocardiogram measurements and blood tests.
CONDITIONS
Official Title
Variations in the Hemostatic System Induced by a Standardized Walking Test
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who have given written informed consent.
- Patients affiliated with or beneficiaries of a social security scheme.
- For the patient group: personal history of provoked venous thromboembolism (venous thrombosis and/or pulmonary embolism) with the last event more than 6 months ago and no indication for long-term antithrombotic prophylaxis.
- Provoked VTE defined by events such as first year of combined estrogen-progestogen contraception, hormonal stimulation for oocyte retrieval, pregnancy and 6 weeks postpartum, surgery, trauma, immobilization, acute infection or inflammation flare, prolonged air travel (≥4 hours), or strict bed rest (≥3 days).
- For the control group: no personal or first-degree family history of venous thromboembolism.
- Controls matched by sex and age within ±5 years of cases.
You will not qualify if you...
- Physical inability to perform the 60-minute walking test, including cardiovascular contraindications like recent acute coronary syndrome, unstable angina, rhythm disorders, severe aortic stenosis, heart failure, acute myocarditis, pericarditis, endocarditis, poorly controlled hypertension (blood pressure > 200/110 mmHg), recent stroke or transient ischemic attack.
- Current or recent (within last month) anticoagulant or antithrombotic treatment.
- Treatment for pulmonary embolism with ongoing dyspnea requiring pulmonary hypertension evaluation.
- Surgery within the last 3 months.
- Known chronic diseases such as diabetes, chronic inflammatory or infectious disease, heart failure, renal or hepatic insufficiency, or arterial thrombosis within last 3 months.
- For women, current or recent (within last month) treatment with synthetic or natural estrogen.
- Pregnancy within the last year.
- Difficult venous access.
- Regular intensive physical activity over 3 hours per week, including activities like running, tennis, or cycling.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Nîmes
Nîmes, Occitanie, France, 30029
Actively Recruiting
Research Team
A
Antonia PEREZ MARTIN, Prof.
CONTACT
A
Anissa MEGZARI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here